- 29th Annual ROTH Conference on March 13, 2017 - - 2016 Fourth Quarter and Full Year Financial Results Conference Call on March 16, 2017 -
VALENCIA, Calif., March 07, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (MNKD) (MNKD) announced two upcoming events:
Presenting at 29th Annual ROTH Conference on Monday, March 13, 2017 at 5:00 pm (PDT) at the Ritz Carlton in Dana Point, California.
To view and listen to the conference webcast, visit MannKind's website at http://www.mannkindcorp.com and click on the "29th Annual ROTH Conference" link in the Webcast section of News & Events.
Release of 2016 fourth quarter and full year financial results on Thursday, March 16, 2017 and management to host a conference call to discuss financial results and other Company developments at 5:00 pm (EDT) on March 16, 2017.
To view and listen to the earning call webcast, visit MannKind's website at http://www.mannkindcorp.com and click on the "Q4 2016 MannKind Earnings Conference Call" link in the Webcast section of News & Events. To participate in the live call by telephone, please dial (888) 771-4371 or (847) 585-4405 and use the participant passcode: 44096370.
A telephone replay of the call will be accessible for approximately 14 days following completion of the call by dialing (888) 843-7419 or (630) 652-3042 and use the participant passcode: 4409 6370#. A replay will also be available on MannKind's website for 14 days.
As with past calls, the Company will take live questions from covering analysts. Stockholders who wish to submit questions in advance of the call should email them to email@example.com. s2
Better Buy: MannKind Corp. vs. Dexcom [Motley Fool] firstname.lastname@example.org (Brian Feroldi) Motley FoolMarch 9, 2017 Better Buy: MannKind Corp. vs. Dexcom America spends more than $322 billion each year treating the 29 million patients who have diabetes or prediabetes. That's a staggering number, so it's not hard to understand why several companies have chosen to specialize in treating this disease. MannKind (NASDAQ:MNKD) and Dexcom (NASDAQ:DXCM) are two such businesses. Both companies have launched innovative products that are designed to make it far easier for patients to manage their disease. But which company is the better bet for new money today? Let's take a closer look at both of them to see if we can ascertain an answer. The case for MannKind Many people with diabetes are forced to inject themselves with insulin multiple times each day.s2
8. The insulin inhaler that eliminates mealtime injections
Afrezza is a mealtime insulin inhaler that is designed to help control blood sugar spikes and lower A1C levels.
Insulin enters the bloodstream through the lungs when Afrezza is inhaled. It reaches maximum insulin levels in 12 to 15 minutes and remains active for up to 3 hours.
While it does help with blood sugar levels during and after a meal, it is not intended to be used as a replacement for long-acting insulin. Afrezza still has to be used with long-acting insulin in people who have Type 1 diabetes.
Afrezza is the only FDA-approved inhaled insulin that helps control blood sugar at mealtime.
ja,genau das was ich meinte,du hast es doch grad selber geschrieben,dass Afrezza quasi überflüssig ist,und wenn du wissen willst wer hier der Nichtcheckerist ,dann schau dir doch bitte deine Threadperformance bei Delcath Systems an,und schau vor allen wie intensiv und lange vorher ich vor dem Schrottpapier gewarnt hab !
Afrezza ist das ideale Insulin zu den Mahlzeiten, in 12-15 Minuten wirkt es und in 2-3 Stunden ist Afrezza wieder aus dem Körper heraus, Hirn einschalten dann Posten, Chalif!
Afrezza und Mannkind hatten es schwer durch das schlechte Label, das ändert sich, die FDA wird Afrezza als erstes Insulin ultra fast acting am 30.09.2017 gewähren, damit ist das real time Monitoring und der einzig superschnellen Behandlung mit Afrezza ein Milliardenmark in Aussicht gestellt, oder Mannkind geht vorher das Geld aus, kapiert?